Cargando…
Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer
SIMPLE SUMMARY: Resistance to oxaliplatin threatens the prognosis in of colorectal cancer (CRC). As previous studies have aroused interest in fatty acid metabolism in cancer, we determined whether fatty acid biosynthesis contribute to oxaliplatin resistance in CRC. By leveraging the GEO databases, F...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913810/ https://www.ncbi.nlm.nih.gov/pubmed/36765520 http://dx.doi.org/10.3390/cancers15030562 |
_version_ | 1784885517963231232 |
---|---|
author | Han, Lingyu Dai, Weixing Luo, Wenqin Ye, Li Fang, Hongsheng Mo, Shaobo Li, Qingguo Xu, Ye Wang, Renjie Cai, Guoxiang |
author_facet | Han, Lingyu Dai, Weixing Luo, Wenqin Ye, Li Fang, Hongsheng Mo, Shaobo Li, Qingguo Xu, Ye Wang, Renjie Cai, Guoxiang |
author_sort | Han, Lingyu |
collection | PubMed |
description | SIMPLE SUMMARY: Resistance to oxaliplatin threatens the prognosis in of colorectal cancer (CRC). As previous studies have aroused interest in fatty acid metabolism in cancer, we determined whether fatty acid biosynthesis contribute to oxaliplatin resistance in CRC. By leveraging the GEO databases, FASN gene signatures was correlated with the response to oxaliplatin-based chemotherapy and poor prognosis. Additionally, FASN expression was positively related with oxaliplatin resistance in vitro. Then, Orlistat, a typical FASN inhibitor, was applied to attenuate the resistance to oxaliplatin in cell culture and xenograft models. Additionally, the combination of the FASN inhibitor and oxaliplatin significantly increased cell cycle arrest and facilitated apoptosis, partly due to the diminished phosphorylation of the MAPK/ERK and PI3K/AKT pathways. Our study revealed that FASN enhanced resistance to oxaliplatin in CRC. Inhibition of FASN could rescue the response to oxaliplatin by regulating MAPK/ERK and PI3K/AKT pathways. ABSTRACT: Background: Oxaliplatin is one of the most widely used chemotherapy drugs for colorectal cancer (CRC). Resistance to oxaliplatin threatens the prognosis of CRC. Since previous studies have aroused interest in fatty acid metabolism in cancer, in this study, we determined whether fatty acid biosynthesis and the related regulating mechanism contribute to oxaliplatin resistance in CRC. Methods: The effect of the fatty acid synthase (FASN) and its inhibitor Orlistat was characterized in Gene Expression Omnibus (GEO) databases, oxaliplatin-resistant cell lines, and xenografts. MRNA-seq and analysis identified related pathway changes after the application of Orlistat, which was verified by Western blotting. Results: By leveraging the GEO databases, FASN and closely related gene signatures were identified as being correlated with the response to oxaliplatin-based chemotherapy and poor prognosis. Additionally, FASN-upregulated expression promoted oxaliplatin resistance in CRC cell lines. We then applied Orlistat, a typical FASN inhibitor, in cell culture and xenograft models of oxaliplatin-resistant CRC, which attenuated the resistance to oxaliplatin. Additionally, the combination of the FASN inhibitor and oxaliplatin significantly increased cell cycle arrest and facilitated apoptosis, partly due to the diminished phosphorylation of the MAPK/ERK and PI3K/AKT pathways. In vivo studies showed that inhibiting fatty acid biosynthesis with Orlistat restrained the growth of xenograft tumors and increased the responsiveness to oxaliplatin. Conclusions: Our study revealed that FASN enhanced resistance to oxaliplatin in CRC. The inhibition of FASN could rescue the response to oxaliplatin by regulating MAPK/ERK and PI3K/AKT pathways. |
format | Online Article Text |
id | pubmed-9913810 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99138102023-02-11 Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer Han, Lingyu Dai, Weixing Luo, Wenqin Ye, Li Fang, Hongsheng Mo, Shaobo Li, Qingguo Xu, Ye Wang, Renjie Cai, Guoxiang Cancers (Basel) Article SIMPLE SUMMARY: Resistance to oxaliplatin threatens the prognosis in of colorectal cancer (CRC). As previous studies have aroused interest in fatty acid metabolism in cancer, we determined whether fatty acid biosynthesis contribute to oxaliplatin resistance in CRC. By leveraging the GEO databases, FASN gene signatures was correlated with the response to oxaliplatin-based chemotherapy and poor prognosis. Additionally, FASN expression was positively related with oxaliplatin resistance in vitro. Then, Orlistat, a typical FASN inhibitor, was applied to attenuate the resistance to oxaliplatin in cell culture and xenograft models. Additionally, the combination of the FASN inhibitor and oxaliplatin significantly increased cell cycle arrest and facilitated apoptosis, partly due to the diminished phosphorylation of the MAPK/ERK and PI3K/AKT pathways. Our study revealed that FASN enhanced resistance to oxaliplatin in CRC. Inhibition of FASN could rescue the response to oxaliplatin by regulating MAPK/ERK and PI3K/AKT pathways. ABSTRACT: Background: Oxaliplatin is one of the most widely used chemotherapy drugs for colorectal cancer (CRC). Resistance to oxaliplatin threatens the prognosis of CRC. Since previous studies have aroused interest in fatty acid metabolism in cancer, in this study, we determined whether fatty acid biosynthesis and the related regulating mechanism contribute to oxaliplatin resistance in CRC. Methods: The effect of the fatty acid synthase (FASN) and its inhibitor Orlistat was characterized in Gene Expression Omnibus (GEO) databases, oxaliplatin-resistant cell lines, and xenografts. MRNA-seq and analysis identified related pathway changes after the application of Orlistat, which was verified by Western blotting. Results: By leveraging the GEO databases, FASN and closely related gene signatures were identified as being correlated with the response to oxaliplatin-based chemotherapy and poor prognosis. Additionally, FASN-upregulated expression promoted oxaliplatin resistance in CRC cell lines. We then applied Orlistat, a typical FASN inhibitor, in cell culture and xenograft models of oxaliplatin-resistant CRC, which attenuated the resistance to oxaliplatin. Additionally, the combination of the FASN inhibitor and oxaliplatin significantly increased cell cycle arrest and facilitated apoptosis, partly due to the diminished phosphorylation of the MAPK/ERK and PI3K/AKT pathways. In vivo studies showed that inhibiting fatty acid biosynthesis with Orlistat restrained the growth of xenograft tumors and increased the responsiveness to oxaliplatin. Conclusions: Our study revealed that FASN enhanced resistance to oxaliplatin in CRC. The inhibition of FASN could rescue the response to oxaliplatin by regulating MAPK/ERK and PI3K/AKT pathways. MDPI 2023-01-17 /pmc/articles/PMC9913810/ /pubmed/36765520 http://dx.doi.org/10.3390/cancers15030562 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Han, Lingyu Dai, Weixing Luo, Wenqin Ye, Li Fang, Hongsheng Mo, Shaobo Li, Qingguo Xu, Ye Wang, Renjie Cai, Guoxiang Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title | Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title_full | Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title_fullStr | Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title_full_unstemmed | Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title_short | Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer |
title_sort | enhanced de novo lipid synthesis mediated by fasn induces chemoresistance in colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913810/ https://www.ncbi.nlm.nih.gov/pubmed/36765520 http://dx.doi.org/10.3390/cancers15030562 |
work_keys_str_mv | AT hanlingyu enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT daiweixing enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT luowenqin enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT yeli enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT fanghongsheng enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT moshaobo enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT liqingguo enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT xuye enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT wangrenjie enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer AT caiguoxiang enhanceddenovolipidsynthesismediatedbyfasninduceschemoresistanceincolorectalcancer |